Date: Wednesday 15th July 2020 Time: 14:00 - 15:00 (BST) Speakers: Bruno Boulanger
Registration:
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
Overview:
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
The value of good design of experiments
Consider Bayesian statistics to answer your question
P-values is not always what you’re looking for
Adopt a life-cycle over the long-run, not just study by study
Speaker Details:
Bruno Boulanger, PharmaLex Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Scientific Meetings
PSI ToxSIG Webinar: Good statistical practices to tackle the lack of reproducibility in preclinical research
Date: Wednesday 15th July 2020 Time: 14:00 - 15:00 (BST) Speakers: Bruno Boulanger
Registration:
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
Overview:
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
The value of good design of experiments
Consider Bayesian statistics to answer your question
P-values is not always what you’re looking for
Adopt a life-cycle over the long-run, not just study by study
Speaker Details:
Bruno Boulanger, PharmaLex Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Training Courses
PSI ToxSIG Webinar: Good statistical practices to tackle the lack of reproducibility in preclinical research
Date: Wednesday 15th July 2020 Time: 14:00 - 15:00 (BST) Speakers: Bruno Boulanger
Registration:
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
Overview:
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
The value of good design of experiments
Consider Bayesian statistics to answer your question
P-values is not always what you’re looking for
Adopt a life-cycle over the long-run, not just study by study
Speaker Details:
Bruno Boulanger, PharmaLex Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Journal Club
PSI ToxSIG Webinar: Good statistical practices to tackle the lack of reproducibility in preclinical research
Date: Wednesday 15th July 2020 Time: 14:00 - 15:00 (BST) Speakers: Bruno Boulanger
Registration:
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
Overview:
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
The value of good design of experiments
Consider Bayesian statistics to answer your question
P-values is not always what you’re looking for
Adopt a life-cycle over the long-run, not just study by study
Speaker Details:
Bruno Boulanger, PharmaLex Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Webinars
PSI ToxSIG Webinar: Good statistical practices to tackle the lack of reproducibility in preclinical research
Date: Wednesday 15th July 2020 Time: 14:00 - 15:00 (BST) Speakers: Bruno Boulanger
Registration:
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
Overview:
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
The value of good design of experiments
Consider Bayesian statistics to answer your question
P-values is not always what you’re looking for
Adopt a life-cycle over the long-run, not just study by study
Speaker Details:
Bruno Boulanger, PharmaLex Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Careers Meetings
PSI ToxSIG Webinar: Good statistical practices to tackle the lack of reproducibility in preclinical research
Date: Wednesday 15th July 2020 Time: 14:00 - 15:00 (BST) Speakers: Bruno Boulanger
Registration:
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
Overview:
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
The value of good design of experiments
Consider Bayesian statistics to answer your question
P-values is not always what you’re looking for
Adopt a life-cycle over the long-run, not just study by study
Speaker Details:
Bruno Boulanger, PharmaLex Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Upcoming Events
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
PSI Training Course: Regulatory Guidelines for Statisticians
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This apprenticeship role offers a unique opportunity to learn and work in a global healthcare consultancy company alongside a team of statisticians, psychometricians and programmers.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK